|1.||Schally, Andrew V: 7 articles (08/2010 - 02/2002)|
|2.||Halmos, Gabor: 7 articles (08/2010 - 02/2002)|
|3.||Nagy, Attila: 4 articles (06/2006 - 02/2002)|
|4.||Seitz, Stephan: 3 articles (08/2010 - 08/2009)|
|5.||Szalontay, Luca: 3 articles (08/2010 - 08/2009)|
|6.||Szepeshazi, Karoly: 3 articles (09/2009 - 02/2002)|
|7.||Halmos, G: 3 articles (09/2001 - 02/2000)|
|8.||Schally, A V: 3 articles (09/2001 - 02/2000)|
|9.||Nagy, A: 3 articles (09/2001 - 02/2000)|
|10.||Buchholz, Stefan: 2 articles (08/2010 - 08/2009)|
|1.||Glioblastoma (Glioblastoma Multiforme)
02/01/2000 - "This study was conducted to investigate the effects of targeted cytotoxic SST analogue AN-238, consisting of 2-pyrrolinodoxorubicin (AN-201), a potent derivative of doxorubicin (DOX) linked to somatostatin analogue RC-121, on the growth of SST receptor-positive U-87 MG human glioblastomas. "
02/01/2002 - "Cytotoxic radical AN-201 administered alone or in an unconjugated mixture with carrier RC-121 inhibited the growth of DU-145 tumors only after the third and fourth injection and was toxic. "
09/01/2001 - "Cytotoxic radical AN-201 or the unconjugated mixture of AN-201 with carrier RC-121 had no significant effects on tumors and were toxic. "
02/01/2000 - "The antitumor effect on AN-238 could be blocked by pretreatment of the tumor-bearing mice with RC-121. "
04/15/1999 - "AN-201, given alone at the same dose or coadministered with RC-121, had no significant effect on PC-3 tumors. "
09/15/1998 - "No reduction in tumor growth or toxic effects was observed with carrier RC-121, but after the injection of unconjugated mixture of AN-201 and RC-121 at doses of 300 nmol/kg, all rats died within 4 days. "
|3.||Colorectal Neoplasms (Colorectal Cancer)
08/01/2010 - "The effect of the targeted cytotoxic somatostatin (SST) analog AN-162, consisting of doxorubicin (DOX) conjugated to SST carrier RC-121, was investigated on the growth of human colorectal cancer (CRC) cell lines HT-29, HCT-15, and HCT-116 and a DOX-resistant mouse leukemia cell line P388/R84. "
02/01/2002 - "Because somatostatin (SRIF) receptors (ssts) are present in colorectal carcinomas, the treatment with targeted cytotoxic SRIF analogue AN-238, consisting of 2-pyrrolinodoxorubicin (AN-201) linked to octapeptide SRIF carrier RC-121, may overcome this resistance by producing a higher concentration of the cytotoxic agent in the tumors. "
|4.||Pancreatic Neoplasms (Pancreatic Cancer)
03/15/1992 - "Nude mice bearing xenografts of MIA PaCa-2 human pancreatic cancer cell line were treated for 4 weeks with AN-51, a somatostatin octapeptide analog D-Phe-Cys-Tyr-D-Trp-Lys-Val-Cys-Thr-NH2 (RC-121) containing methotrexate attached to the alpha-amino group of D-Phe in position 1. Control groups of mice received saline, RC-121 or methotrexate. "
09/01/2001 - "We investigated whether SSTRs on human pancreatic cancer lines xenografted into nude mice can be used for targeting of cytotoxic somatostatin analogue AN-238, consisting of 2-pyrrolinodoxorubicin (AN-201) linked to octapeptide carrier RC-121. "
|5.||Small Cell Lung Carcinoma (Small Cell Lung Cancer)
|1.||Somatostatin (Somatotropin Release-Inhibiting Factor)
|3.||AN 204 (AN 201)
|6.||Somatostatin Receptors (Somatostatin Receptor)
|8.||Gonadotropin-Releasing Hormone (GnRH)
|1.||Heterologous Transplantation (Xenotransplantation)